Discussion on solving drug-resistant issues using antibody-based drugs
DOI:
https://doi.org/10.61173/eccrtg02Keywords:
Antibody-Drug Conjugates (ADCs), Anti-microbial Resistance, Monoclonal Antibodies, Targeted Therapy, Alternative TherapeuticsAbstract
As the problem of drug resistance increases, which dramatically threatens current therapies, all public health-related agencies are trying to find potential solutions to these issues. Most efforts are focused on the drugs themselves, searching for alternative substances with different actions and mechanisms to inhibit or kill resistant pathogens. However, it may be beneficial to approach the problem from a different perspective. Antibodies, a type of polypeptide usually produced during the adaptive immune response, have begun to show considerable potential in solving these problems. Currently, antibody-conjugate drugs have shown excellent results in the treatment of cancers and, in some cases, viral infections. Thus, the hypothesis has been proposed that using antibodies or antibody-based drugs could treat diseases such as common bacterial or viral infections. Therefore, this may provide alternative approaches for solving these problems.
References
[1] J. Tanwar, S. Das, Z. Fatima, S. Hameed, Multidrug resistance: an emerging crisis. Interdiscip. Perspect. Infect. Dis. 2014:541340 (2014) Dean&Francis ISSN 2959-409X
[2] B. Spellberg, J. G. Bartlett, D. N. Gilbert, The future of antibiotics and resistance. N. Engl. J. Med. 368:299-302 (2013)
[3] J. M. A. Blair, M. A. Webber, A. J. Baylay, D. O. Ogbolu, L. J. V. Piddock, Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13:42-51 (2015)
[4] Z. X. Phuna, P. A. Kumar, E. Haroun, D. Dutta, and S. H. Lim, Antibody-drug conjugates: Principles and opportunities. Life Sci. 347:122676 (2024)
[5] C. H. Song, M. Jeong, H. In, J. H. Kim, C.-W. Lin, and K. H. Han, Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies. 12:72 (2023)
[6] Z. Fu, S. Li, S. Han, C. Shi, and Y. Zhang, Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 7:247 (2022)
[7] R.F. Seipke, M. Kaltenpoth, and M. I. Hutchings, Streptomyces as symbionts: an emerging and widespread theme? FEMS Microbiol. Rev. 36:862-876 (2011)
[8] J.L. Klassen, Microbial secondary metabolites and their impacts on insect symbioses. Curr. Opin. Insect Sci. 4:15-22 (2014)
[9] M.F.Traxler, R. Kolter, Natural products in soil microbe interactions and evolution. Nat. Prod. Rep. 32:956-970 (2015)
[10] P. Shree, C. K. Singh, K. K. Sodhi, J. N. Surya, and D. K. Singh, Biofilms: understanding the structure and contribution towards bacterial resistance in antibiotics. Med. Microecol. 16:100084 (2023)
[11] A. Fàbrega, S. Madurga, E. Giralt, and J. Vila, Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2:40- 61 (2009)
[12] E.M. Halawa, M. Fadel, M.W. Al-Rabia, A. Behairy, N.A. Nouh, M. Abdo, R. Olga, L. Fericean, A.M. Atwa, M. El- Nablaway, and A. Abdeen, Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Front. Pharmacol. 14:1305294 (2024)
[13] W.S. Champney, The other target for ribosomal antibiotics: inhibition of bacterial ribosomal subunit formation. Infect. Disord. Drug Targets. 6:377-390 (2008)
[14] A. H. Delcour, Outer membrane permeability and antibiotic resistance. Biochim. Biophys. 1794:808-816 (2009)
[15] Q. Vicens and E. Westhof, RNA as a drug target: the case of aminoglycosides. ChemBioChem 4:1018-1023 (2003)
[16] J.M. Munita and C. A. Arias, Mechanisms of Antibiotic Resistance. Microbiol. Spectr. 4 (2016)
[17] J.M. Manson, L.E. Hancock, and M.S. Gilmore, Mechanism of chromosomal transfer of Enterococcus faecalis pathogenicity island, capsule, antimicrobial resistance, and other traits. Proc. Natl. Acad. Sci. U.S.A. 107:12269-12274 (2010)
[18] D.Ä.G.R.D. Ärzteblatt, The Diagnosis and Treatment of Tuberculosis. Deutsches Rzteblatt (2019).
[19] The Editors of Encyclopaedia Britannica, Antibody | Definition, Structure, Function, & Types. Encyclopedia Britannica (2025).
[20] S. Perdue, S. Scott, J. Humphrey, and H. J. (Encyclopedia Britannica), Immune system | Description, Function, & Facts. Encyclopedia Britannica (2025)
[21] D. Jarczak and A. Nierhaus, Cytokine Storm-Definition, Causes, and Implications. Int. J. Mol. Sci. 23:11740 (2022)
[22] National Institute of Diabetes and Digestive and Kidney Diseases, Monoclonal antibodies. LiverTox - NCBI Bookshelf (2025)
[23] S.C. Oostindie, G.A. Lazar, J. Schuurman, and P.W.H.I. Parren, Avidity in antibody effector functions and biotherapeutic drug design. Nat. Rev. Drug Discov. 21:715-735 (2022)
[24] K. Tsuchikama and Z. An, Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 9:33-46 (2016)
[25] P. J. Carter and A. Rajpal, Designing antibodies as therapeutics. Cell. 190:1-21 (2022)
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
